Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]

  • Awaiting development
  • GID-TA11754
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Lisocabtagene Maraleucel within its marketing authorisation for treating Follicular Lymphoma